Sorafenib is an orally active, multikinase inhibitor that inhibits tumour angiogenesis and cell proliferation by blocking cell surface tyrosine kinases such as vascular endothelial growth factor receptor-2/3 (VEGFR-2/3) and platelet derived growth factor receptor beta, as well as downstream signalling pathways involving the serine/threonine kinases Raf-1 and B-Raf [13]. The gene discussed is MARK2; the disease is neoplasm.